Interestingly, in this subgroup, patients had a significantly lower 5-year EFS compared to patients without expression of HER2/neu (63,0% versus 80,5%, p=0.02). In conclusion, these 4 antigens could be alternatives of interest especially since CD19 can be downmodulated after current therapies targeting this antigen. Trastuzumab could also be a potential interesting immunotherapy in the HER2/neu expressing group, especially in relapsed childhood ALL.